Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized Double-blind Study of KAR Lotion in Treatment-resistant Head Lice
jRCT2031220028Completed
- Sponsor
- Kaken Pharmaceutical Co., Ltd.
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in pediculosis capitis comparing KAR 0.5% lotion with KAR 0% lotion (vehicle control) (2 arms). Primary endpoint: Successful treatment of index subject. Started Jul 2022; status: completed.
02
Drugs
ivermectin
03
Conditions
pediculosis capitis
Beyond the preview
Go deeper on jRCT2031220028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220028.